Media & Resources

Call it a sheep in wolf’s clothing. Researchers with the International Aids Vaccine Initiative (IAVI) and The Scripps Research Institute (TSRI) have built tiny particles that resemble HIV on their outside and used them to provoke an immune response in animals. Their work, which was published today in the journal Cell Reports, could advance the…

A sub-Saharan African donor’s blood has yielded remarkable finds that could be crucial in the search for an AIDS vaccine. An infected donor’s immune system naturally made potent antibodies, which lab tests showed could effectively recognize and neutralize about 50 percent of all HIV-1 strains circulating around the world. HIV-1 is the most widespread HIV…

Engineered vaccine protein binds key immune cells that exist in nearly everyone.

Data published this month demonstrated the immunogenicity and good safety profile of two novel platforms for potential use in a preventive AIDS vaccine.

The International AIDS Vaccine Initiative (IAVI) welcomes new data from two late-stage clinical studies indicating that vaginal rings containing the antiretroviral drug dapivirine can safely help protect vulnerable women in sub-Saharan Africa from HIV infection.

The International AIDS Vaccine Initiative (IAVI) is pleased to welcome two new senior members to its vaccine design and development teams.

The International AIDS Vaccine Initiative (IAVI) is happy to announce continued funding from the Dutch Government, a longtime partner in the mission to ensure a safe, effective and accessible AIDS vaccine.

The International AIDS Vaccine Initiative (IAVI) is pleased to announce its partnership in the European HIV Vaccine Alliance (EHVA), a new research consortium to develop innovative HIV vaccine concepts. Funded by a European Union grant under the Horizon 2020 health program, the consortium convenes 39 industrial and academic partners from Europe, the United States and…